DHA’s $41M Wafermine Award Faces U.S. Manufacturing Licensing Risk

The Defense Health Agency (DHA) awarded Singapore-based iX Biopharma a nearly $41 million sole-source development contract in February 2026 for Wafermine, a ketamine wafer designed to dissolve under the tongue. The Pentagon’s interest is in a battlefield option for acute moderate to severe pain that could be administered without an injection. iX Biopharma has described Wafermine as the “world’s first sublingual ketamine for acute moderate to severe pain,” using absorption through the mucous membrane into the bloodstream. The contract is already in execution: iX Biopharma is the awardee, and the available reporting describes development and manufacturing readiness—not a current solicitation or competition for the work.

The product’s potential route to use has a significant regulatory dependency. On September 3, 2026, the U.S. Department of Health and Human Services issued an emergency-use declaration following a July 15 determination by Defense Secretary Pete Hegseth concerning a military emergency, or significant potential for one, involving heightened risk to U.S. forces from chemical, biological, radiological, or nuclear agents. The declaration said related injuries could cause moderate to severe acute pain and risk life-threatening hemodynamic instability, including shock or respiratory distress. It created a pathway for the Food and Drug Administration (FDA) to authorize emergency use of drugs identified by the Pentagon; it did not name Wafermine or itself authorize the product. iX Biopharma is pursuing an emergency-use authorization filing, so the declaration should not be treated as approval for this specific medicine.

Manufacturing readiness presents a separate schedule risk. According to the reported information, proposed U.S. manufacturing partner Orion Specialty Labs LLC has not obtained the Nevada pharmacy license required to operate. Orion’s next opportunity to seek approval is in early December 2026. That milestone matters to iX Biopharma’s stated target of making Wafermine available to U.S. troops in 2027, but the available information does not establish that the license will be granted or that manufacturing arrangements are final. iX Biopharma Chief Commercial Officer Eva Tan said the company is “currently working through the various requirements and conditions relating to manufacturing and supply, and no final arrangements have been confirmed at this stage.”

For GovCon suppliers, the award illustrates why a funded development contract does not by itself resolve downstream deployment constraints. The immediate monitoring points are the emergency-use filing and FDA decision pathway, Orion’s state licensing process, and confirmation of manufacturing and supply arrangements. Pharmaceutical manufacturers and potential subcontractors assessing domestic production roles should account for state-level licensing, facility readiness, and regulatory dependencies when estimating schedule or proposing support. Since the contract is sole-source and already awarded, the procurement opportunity for other firms is more likely to arise through future subcontracting or supporting supply-chain roles than through competition for this existing award.

• Award status: DHA made a nearly $41 million sole-source development award to iX Biopharma in February 2026; it is an execution program, not an open competition.
• Product: Wafermine is a sublingual ketamine wafer being developed for acute moderate to severe battlefield pain relief.
• Emergency-use pathway: The September 3, 2026 HHS declaration establishes a potential authorization route but does not identify Wafermine or authorize its use.
• Regulatory watch: iX Biopharma is pursuing an emergency-use authorization filing; FDA action remains a key dependency for potential deployment.
• Manufacturing constraint: Proposed U.S. manufacturer Orion Specialty Labs LLC has not obtained the Nevada pharmacy license required to operate.
• Next licensing milestone: Orion’s next opportunity to seek Nevada approval is in early December 2026; approval and timing remain uncertain.
• Schedule target: iX Biopharma has targeted U.S. troop availability in 2027, subject to authorization, licensing, and production readiness.
• Supply-chain status: Eva Tan said manufacturing and supply requirements are being worked through and that “no final arrangements have been confirmed at this stage.”
• Business-development implication: Suppliers should monitor subcontracting and domestic production support needs while accounting for state licensing and pharmaceutical readiness requirements.